Commentary

Video

Hodgkin Lymphoma: Overview and Update

Author(s):

Ann S. LaCasce, MD, MMSc

Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.

Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.

Related Videos
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Estelamari Rodriguez, MD
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Brian A. Van Tine, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
Nirav N. Shah, MD
January 7th 2025

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Margaret A. Shipp, MD, of Dana-Farber
December 31st 2024

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology